GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » Total Long-Term Liabilities

Galapagos NV (Galapagos NV) Total Long-Term Liabilities : $1,236.2 Mil (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Galapagos NV's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was $1,236.2 Mil.

Galapagos NV Total Long-Term Liabilities Historical Data

The historical data trend for Galapagos NV's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Long-Term Liabilities Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,912.40 2,934.43 2,241.04 1,785.79 1,236.21

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,785.79 1,653.82 1,585.40 1,478.91 1,236.21

Galapagos NV Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Galapagos NV Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » Total Long-Term Liabilities
Comparable Companies
XAMS:PHARM XAMS:BAI XAMS:VVY OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX OCSE:GMAB ALNY BGNE BMRN SZSE:300122 RPRX INCY
Traded in Other Exchanges
GLPG:USA GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Website
https://www.glpg.com
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.